5 most recent filings and news items mentioning BBIO. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/BBIO/news?limit=20"
Pull BBIO filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayBridgeBio Pharma announced FDA acceptance of a new drug application for encaleret targeting autosomal dominant hypocalcemia type 1, setting a target action date of May 8, 2027, and representing a potential blockbuster opportunity for the company.
View filing at SEC.gov →BridgeBio Pharma Inc filed a certificate designating 933,900 shares of Series A cumulative preferred stock. This corporate equity designation is a standard capitalization update with no immediate impact on operations.
View filing at SEC.gov →BridgeBio Pharma filed a Third Amended and Restated 2021 Stock Option and Incentive Plan. The update aims to expand equity compensation opportunities to align key personnel interests with shareholder value.
View filing at SEC.gov →Boundless Bio entered into a merger agreement with Serapha Bio to combine in an all-stock deal. Shareholder approval is required to complete the reorganization.
View filing at SEC.gov →BridgeBio announced FDA acceptance of its New Drug Application for BBP-418 to treat LGMD2I/R9, a rare genetic muscular dystrophy, with a Priority Review designation and potential November 2026 approval. If approved, BBP-418 would be the first therapy for LGMD2I/R9 and the first a
View filing at SEC.gov →